Mike Hamill

Mike Hamill joined Flagship Pioneering in 2021 and serves as an Origination Partner, where he builds new biotech ventures by translating scientific breakthroughs into repeatable discovery platforms and company-forming strategies. He works across therapeutics and health innovation, leading close collaborations with AI teams to conceive and build platform engines that generate high-value products and compounding advantage over time.

Mike is also a Co-Founder of Abiologics, where he helped establish the first closed-loop design platform for fully synthetic proteins built from D-amino acids, creating a new protein modality and opening a distinct therapeutic design space. Mike’s leadership has driven cross-functional execution spanning novel chemistry and generative design to translate this modality into programmable protein therapeutics that behave unlike conventional proteins, with exceptional stability, durability, and developability.

Previously, Mike served as Vice President and Head of Research at Axcella Therapeutics, a Flagship Pioneering company, where he helped conceive and build a platform approach to metabolic modulation and led programs from discovery through clinical-stage development.

He earned a Ph.D. in Biochemistry from Boston University and a B.S. in Chemistry from Gettysburg College.